Regeneron Pharmaceuticals, Inc. Description
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Related Macular Degeneration
Human Monoclonal Antibodies
Metastatic Colorectal Cancer